BiotechTube
Northway Biotech

Northway Biotech

Vilnius, Europe - Other· Est.
northwaybiotech.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $15M

Overview

Northway Biotech is a well-established, privately-held CDMO with over 20 years of technical expertise, serving a global client base from its facilities in Lithuania and Massachusetts. The company provides a vertically integrated service model for biologics and gene therapy development and manufacturing, positioning itself as a strategic partner for biopharmaceutical companies from preclinical through commercial stages. With a strong leadership team and continuous facility expansion, Northway Biotech is capitalizing on the growing demand for outsourced bioproduction capabilities.

BiologicsAntibodies

Technology Platform

Integrated CDMO platform for protein-based biologics (mammalian/microbial) and gene therapies (pDNA/viral vectors), offering end-to-end services from cell line development to commercial cGMP manufacturing and aseptic fill-finish.

Funding History

2
Total raised:$15M
Debt$5M
Series A$10M

Opportunities

The booming global market for biologics and gene therapies, coupled with the strong industry trend toward outsourcing, provides a massive growth runway.
Northway's cost-competitive EU base combined with a strategic US facility allows it to effectively serve both major biopharma markets and capitalize on the rapid expansion of the cell and gene therapy sector.

Risk Factors

Intense competition from larger, global CDMOs poses a constant threat to market share and pricing.
Operational risks, including potential manufacturing failures or regulatory non-compliance, could severely damage the company's reputation.
Geopolitical instability in Eastern Europe and macroeconomic downturns affecting biotech funding are external risk factors.

Competitive Landscape

Northway Biotech competes in a fragmented but competitive global CDMO market, facing large players like Lonza, Catalent, and Samsung Biologics, as well as many specialized mid-sized and regional CDMOs. Its differentiation lies in its integrated end-to-end service for both biologics and gene therapies, its EU/US dual-location strategy, and a collaborative partnership model appealing to mid-sized biotechs.

More companies in Biologics / Biosimilars →More companies in Europe - Other →